Please assess the completion status of the following clinical trial:

Trial Title: Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:~* Has previously undergone BEAC or BEAM autologus SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification - only B-cell lymphomas are permitted.~* ECOG performance status 0-1.~* Previously histological documented CD20 +NHL.~* Is greater than 18 years of age.~* Is 30-100 days from autologous peripheral blood stem cell transplant.~* Must meet laboratory values (see protocol for values): Absolute neutrophils, hemoglobin and platelets.~* Has a negative serum pregnancy test within 7 days prior to trial registration (only for female patients of childbearing potential).~* If fertile, patient (male or female) has agreed to use physician-approved method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.~* Has signed a Patient Informed Consent Form.~* Has signed a Patient Authorization Form (HIPAA).~EXCLUSION CRITERIA:~Patients will be taken off treatment if any of the following occur:~* ECOG PS \>2.~* A history of hypersensitivity to study drugs, or any component thereof, or anaphylactic history to murine protein.~* Manifested cardiac complications during transplant, including arrthymias, congestive heart failure, angina, or myocardial infarct, or had a decreased LVEF to \<45% prior to transplant~* On systemic corticosteroids.~* Diffusion capacity \<60% (corrected) and has decreased 30% or more following transplant~* Documented disease progression (See Section 10.1.6 for definition).~* Active infection, and/or is known to be seropositive for hepatitis B, hepatitis C, or HIV~* Pericardial effusion, pleural effusions, or ascites.~* A history of very aggressive NHL, such as Burkitt's or atypical Burkitt's lymphoma~* Receiving concurrent immunotherapy or rituximab therapy.~* Previously received a solid organ transplant.~* History of CNS involvement.~* A serious uncontrolled intercurrent medical or psychiatric illness, including serious infection~* A history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.~* A pregnant or nursing woman.~* Unable to comply with requirements of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).